Leonard P. James
About
Leonard P. James is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Leonard P. James has authored 29 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Leonard P. James's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (7 papers) and Cancer therapeutics and mechanisms (5 papers). Leonard P. James is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (7 papers) and Cancer therapeutics and mechanisms (5 papers). Leonard P. James collaborates with scholars based in United States, Australia and Italy. Leonard P. James's co-authors include Robert N. Eisenman, Shaun M. Cowley, Carla Grandori, Mark G. Kris, Alice T. Shaw, Jean‐François Martini, Benjamin Solomon, Jill S. Clancy, Michelle S. Ginsberg and Enriqueta Felip and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.
In The Last Decade
Leonard P. James
29 papers receiving 2.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Leonard P. James United States | 16 | 1.4k | 1.1k | 1.1k | 378 | 313 | 29 | 2.7k | ||
| Katherine Crosby United States | 14 | 1.6k 1.1× | 1.2k 1.1× | 1.3k 1.2× | 382 1.0× | 193 0.6× | 19 | 2.7k | ||
| Colby L. Eaton United Kingdom | 31 | 1.5k 1.0× | 873 0.8× | 1.4k 1.4× | 648 1.7× | 283 0.9× | 80 | 2.9k | ||
| Carrie A. Adelman United States | 17 | 1.6k 1.1× | 1.4k 1.3× | 1.5k 1.4× | 729 1.9× | 236 0.8× | 29 | 3.0k | ||
| Ole J. Halvorsen Norway | 26 | 1.6k 1.1× | 1.2k 1.1× | 738 0.7× | 748 2.0× | 304 1.0× | 79 | 3.0k | ||
| Daniel Nava Rodrigues United Kingdom | 26 | 948 0.7× | 1.0k 1.0× | 878 0.8× | 820 2.2× | 177 0.6× | 54 | 2.2k | ||
| Robert A. Sikes United States | 31 | 1.6k 1.1× | 1.3k 1.2× | 956 0.9× | 608 1.6× | 178 0.6× | 71 | 3.3k | ||
| Robert Veve United States | 10 | 934 0.7× | 1.3k 1.2× | 1.3k 1.2× | 336 0.9× | 232 0.7× | 12 | 2.3k | ||
| T. Khanh United States | 26 | 1.6k 1.1× | 462 0.4× | 991 0.9× | 473 1.3× | 422 1.3× | 57 | 2.5k | ||
| Raffael Kurek Germany | 18 | 963 0.7× | 721 0.7× | 1.0k 1.0× | 563 1.5× | 161 0.5× | 39 | 2.2k | ||
| Bungo Furusato United States | 26 | 1.1k 0.8× | 1.4k 1.3× | 759 0.7× | 618 1.6× | 132 0.4× | 63 | 2.7k |
Countries citing papers authored by Leonard P. James
Since
Specialization
Citations
This map shows the geographic impact of Leonard P. James's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonard P. James with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonard P. James more than expected).
Fields of papers citing papers by Leonard P. James
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Leonard P. James. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonard P. James. The network helps show where Leonard P. James may publish in the future.
Co-authorship network of co-authors of Leonard P. James
This figure shows the co-authorship network connecting the top 25 collaborators of Leonard P. James. A scholar is included among the top collaborators of Leonard P. James based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonard P. James. Leonard P. James is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chen, Joseph, Ana Ruiz-Garcı́a, Leonard P. James, et al.. (2021). Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer. Clinical Pharmacology & Therapeutics. 110(5). 1273–1281.
2.
Chen, Joseph, Huiping Xu, Sylvester Pawlak, et al.. (2019). The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants. Advances in Therapy. 37(2). 745–758.
3.
Besse, Benjamin, Alice T. Shaw, Benjamin Solomon, et al.. (2017). Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v465–v466.
4.
Shaw, Alice T., Enriqueta Felip, Todd M. Bauer, et al.. (2017). Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. The Lancet Oncology. 18(12). 1590–1599.
5.
Shaw, Alice T., Sai‐Hong Ignatius Ou, Enriqueta Felip, et al.. (2017). Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.. Journal of Clinical Oncology. 35(15_suppl). 9006–9006.
6.
Martin, Peter, Paul M. Barr, Leonard P. James, Ashutosh Pathak, & Brad S. Kahl. (2017). Long-term safety experience with bendamustine for injection in a real-world setting. Expert Opinion on Drug Safety. 16(6). 647–650.
7.
Jänne, Pasi A., Alice T. Shaw, D. Ross Camidge, et al.. (2016). Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study. Journal of Thoracic Oncology. 11(5). 737–747.
8.
Bauer, Todd M., Alice T. Shaw, Benjamin Solomon, et al.. (2015). Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.. Journal of Clinical Oncology. 33(15_suppl). TPS2620–TPS2620.
9.
Oxnard, Geoffrey R., Binsheng Zhao, Camelia S. Sima, et al.. (2011). Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes. Journal of Clinical Oncology. 29(23). 3114–3119.
10.
Paik, Paul K., Charles M. Rudin, M. Catherine Pietanza, et al.. (2011). A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 74(3). 481–485.
11.
Paik, Paul K., Leonard P. James, Gregory J. Riely, et al.. (2011). A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion. Cancer Chemotherapy and Pharmacology. 68(5). 1331–1337.
12.
Azzoli, Christopher G., Jyoti D. Patel, Lee M. Krug, et al.. (2011). Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial. Journal of Thoracic Oncology. 6(11). 1915–1922.
13.
Paik, Paul K., Charles M. Rudin, Andrew Brown, et al.. (2010). A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 66(6). 1079–1085.
14.
Zhao, Binsheng, Leonard P. James, Chaya S. Moskowitz, et al.. (2009). Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer. Radiology. 252(1). 263–272.
15.
James, Leonard P., Christopher G. Azzoli, Lee M. Krug, et al.. (2007). Phase I study of the anitfolate pralatrexate given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 6.
16.
James, Leonard P., Valerie W. Rusch, Binsheng Zhao, et al.. (2007). P3-097: Regressions 14 days following bevacizumab as a single agent as part of neoadjuvant chemotherapy for resectable non–squamous NSCLC. Journal of Thoracic Oncology. 2(8). S720–S720.
17.
James, Leonard P., Mark G. Kris, R T Heelan, et al.. (2007). A phase II study to determine if sensory neuropathy of nab-paclitaxel can be reduced by prolonging infusion in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 18087–18087.
18.
Kearns, Gregory L., Géraldine M. Ferron, Leonard P. James, et al.. (2003). Pantoprazole Disposition in Pediatrics. Clinical Pharmacology & Therapeutics. 73(2).
19.
James, Leonard P. & Robert N. Eisenman. (2002). Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo. Proceedings of the National Academy of Sciences. 99(16). 10429–10434.
20.
Grandori, Carla, Shaun M. Cowley, Leonard P. James, & Robert N. Eisenman. (2000). The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior. Annual Review of Cell and Developmental Biology. 16(1). 653–699.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Katherine Crosby Breakdown of academic impact, for papers by Colby L. Eaton Breakdown of academic impact, for papers by Carrie A. Adelman Breakdown of academic impact, for papers by Ole J. Halvorsen Breakdown of academic impact, for papers by Daniel Nava Rodrigues Breakdown of academic impact, for papers by Robert A. Sikes Breakdown of academic impact, for papers by Robert Veve Breakdown of academic impact, for papers by T. Khanh Breakdown of academic impact, for papers by Raffael Kurek Breakdown of academic impact, for papers by Bungo Furusato